Download PDF
Exp Clin Endocrinol Diabetes 2011; 119(8): 472-479
DOI: 10.1055/s-0031-1279713
Review

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

The Evidence for the Use of Growth Factors and Active Skin Substitutes for the Treatment of Non-Infected Diabetic Foot Ulcers (DFU): A Health Technology Assessment (HTA)

B. Buchberger1 , M. Follmann2 , D. Freyer1 , H. Huppertz1 , A. Ehm1 , J. Wasem1
  • 1University of Duisburg-Essen, Essen, Germany
  • 2German Cancer Society, Berlin, Germany
Further Information

Publication History

received 11.12.2010 first decision 15.03.2011

accepted 06.05.2011

Publication Date:
02 August 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Aims: Assessment of the safety, efficacy and effectiveness of growth factors alone or in combination with other technologies in the treatment of DFU including medical, economical, social, ethical and juridical aspects.

Methods: We systematically searched relevant data bases limited to English and German language and publications since 1990. Review and assessment of the quality of publications followed methods conforming to widely accepted standards for evidence-based medicine and health economics.

Results: We identified 25 studies comparing becaplermin, rhEGF, bFGF and the metabolically active skin grafts Dermagraft and Apligraf with standard wound care (SWC) alone or extracellular wound matrix. Study duration ranged from 12 to 20 weeks and the study population comprised between 17 and 382 patients. Treatment with becaplermin, rhEGF, Dermagraft and Apligraf resulted in a higher incidence of complete wound closure and shorter time to complete wound healing with statistically significant differences. Regarding the proportion of adverse events there was no difference between treatment groups. The methodological quality of the studies was affected by significant deficiencies. Economic evaluations showed becaplermin being cost-effective.

Conclusions: Add-on therapy with growth factors and active skin substitutes for treating uncomplicated DFU could be an alternative to SWC alone. For explicit recommendations further studies with stronger evidence are necessary.

Key words

diabetic foot - ulcer - growth factors - wound healing

References

  • 1 Wild S, Roglic G, Green A. et al . Prevalence of diabetes: estimates for the year 2000 and projections for 2030.  Diabetes Care. 2004;  27 (10) 1047-1053
    Google Scholar
  • 2 Bakker K, Riley P. The year of the diabetic foot.  DiabetesVoice. 2005;  50 (1) 11-14
    Google Scholar
  • 3 World Health Organization WHO . World Diabetes Day: too many people are losing lower limbs unnecessarily to diabetes [cited 2010 Apr 15].  Available from http://www.who.int/mediacentre/news/releases/2005/pr61/en/index.html 2010; 
    Google Scholar
  • 4 Buchberger B, Follmann M, Freyer D. et al . Bedeutung von Wachstumsfaktoren für die Behandlung von chronischen Wunden am Beispiel des diabetischen Fußulcus.  Köln: DAHTA@DIMDI; Available from http://portal.dimdi.de/de/hta/hta_berichte/hta262_bericht_de.pdf 2010; 
    Google Scholar
  • 5 Moher D, Schulz KF, Altman DG. for the CONSORT group . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.  Lancet. 2001;  357 1191-1194
    Google Scholar
  • 6 Siebert U, Behrend C, Mühlberger N. et al .Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland. In: Leidl R, Schulenburg JM Graf von der, Wasem J (eds). Ansätze und Methoden der ökonomischen Evaluation – eine internationale Perspektive. Health Technology Assessment, Bd. 9. Baden-Baden: Nomos; 1999: 156-170
    Google Scholar
  • 7 Marston WA, Hanft J, Norwood P for the Dermagraft Diabetic Foot Ulcer Study Group et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Results of a prospective randomized trial.  Diabetes Care. 2003;  26 1701-1705
    Google Scholar
  • 8 Edmonds M. European and Australian Apligraf Diabetic Foot Ulcer Study Group . Apligraf in the treatment of neuropathic diabetic foot ulcers.  Int J Low Extrem Wounds. 2009;  8 (1) 11-18
    Google Scholar
  • 9 Bhansali A, Venkatesh S, Dutta P. et al . Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?.  Diabetes Res Clin Pract. 2009;  83 (1) e13-e16
    Google Scholar
  • 10 d’Hemecourt PA, Smiell JA, Karim MR. Sodium Carboxymethylcellulose Aqueous-Based Gel vs. Becaplermin Gel in Patients with Nonhealing Lower Extremity Diabetic Ulcers.  Wounds. 1998;  10 (3) 69-75
    Google Scholar
  • 11 Hardikar JV, Chiranyeev Reddy Y, Deen Dayal Bung. et al and the HEALACE Study Group Efficacy of recombinant human platelet-derived growth factor (rhPDGF) based Gel in diabetic foot ulcers: A randomized, multicenter, double-blind, placebo-controlled study in India.  Wounds. 2005;  17 (6) 141-152
    Google Scholar
  • 12 Steed and the Diabetic Ulcer Study Group . Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers.  J Vasc Surg. 1995;  21 (1) 71-81
    Google Scholar
  • 13 Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (Becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.  Diabetes Care. 1998;  21 (5) 822-827
    Google Scholar
  • 14 Niezgoda JA, Van Gils CC, Frykberg RG and the Oasis Diabetic Ulcer Study Group et al. Randomized clinical trial comparing Oasis wound matrix to Regranex gel for diabetic ulcers.  Adv Skin Wound Care. 2005;  18 (5) 258-266
    Google Scholar
  • 15 Tsang MW, Wong WKR, Hung CS. et al . Human epidermal growth factor enhances healing of diabetic foot ulcers.  Diabetes Care. 2003;  26 (6) 1856-1861
    Google Scholar
  • 16 Viswanathan V, Pendsey S, Sekar N. et al . A phase III study to evaluate the safety and efficacy of recombinant human epidermal growth factor (REGEN-DTM 150) in healing diabetic foot ulcers.  Wounds. 2006;  18 (7) 186-196
    Google Scholar
  • 17 Richard JL, Parer-Richard C, Daures JP. et al . Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study.  Diabetes Care. 1995;  18 (1) 64-69
    Google Scholar
  • 18 Gentzkow GD, Iwasaki SD, Hershon KS. et al . Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers.  Diabetes Care. 1996;  19 (4) 350-354
    Google Scholar
  • 19 Hanft JR, Surprenant MS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis.  J Foot Ankle Surg. 2002;  41 (5) 291-299
    Google Scholar
  • 20 Pollak RA, Edington H, Jensen JL. et al and the Dermagraft Diabetic Ulcer Study Group A human dermal replacement for the treatment of diabetic foot ulcers.  Wounds. 1997;  9 (6) 175-183
    Google Scholar
  • 21 Robson MC, Payne WG, Garner WL. et al . Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) Gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers.  J Appl Res. 2005;  5 (1) 35-45
    Google Scholar
  • 22 Smiell JM, Wieman TJ, Steed DL. et al . Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.  Wound Repair. 1999;  7 (5) 335-346
    Google Scholar
  • 23 Ghatnekar O, Persson U, Willis M. et al . The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel.  J Drug Asses. 2000;  3 243-251
    Google Scholar
  • 24 Ghatnekar O, Persson U, Willis M. et al . Cost Effectiveness of Becaplermin in the Treatment of Diabetic Foot Ulcers in Four European Countries.  Pharmacoeconomics. 2001;  19 (7) 767-778
    Google Scholar
  • 25 Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis (Structured abstract).  Dermatol Surg. 2001;  27 (4) 347-351
    Google Scholar
  • 26 Persson U, Willis M, Ödegaard K. et al . The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data (Structured abstract).  Value in Health. 2000;  3 39-46
    Google Scholar
  • 27 Sibbald RG, Torrance G, Hux M. et al . Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.  Ostomy Wound Manage. 2003;  49 (11) 76-84
    Google Scholar
  • 28 Allenet B, Parée F, Lebrun T. et al . Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context.  Diabetes Metab. 2000;  26 (2) 125-132
    Google Scholar
  • 29 Segal L, John S. The use of dermagraft in neuropathic foot ulcers in people with diabetes: an economic analysis in Australia.  Primary Intention. 10 (2) 49-57
    Google Scholar
  • 30 Redekop WK, McDonnell J, Verboom P. et al . The cost effectiveness of Apligraf treatment of diabetic foot ulcers.  Pharmacoeconomics. 2003;  21 (16) 1171-1183
    Google Scholar
  • 31 Steinberg J, Beusterien K, Plante K. et al . A cost analysis of a living skin equivalent in the treatment of diabetic foot ulcers.  Wounds. 2002;  14 142-149
    Google Scholar
  • 32 Roehrig B, du Prel J-B, Blettner M. Studiendesign in der medizinischen Forschung Teil 2 der Serie zur Bewertung wissenschaftlicher Publikationen.  Dtsch Arztebl Int. 2009;  106 (11) 184-189
    Google Scholar
  • 33 Schulz KF, Grimes DA. Blinding in randomised trials: hiding who got what.  Lancet. 2002;  359 696-700
    Google Scholar
  • 34 Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering.  Lancet. 2002;  359 614-618
    Google Scholar
  • 35 Higgins JPT, Green S. eds Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated 2006 September; cited 2010 Jan 05], section 6.  Available from: http://www.cochrane.org/sites/default/files/uploads/Handbook4.2.6Sep2006.pdf 2006; 
    Google Scholar
  • 36 Steed DL. Clinical Evaluation of Recombinant Human Platelet-Derived Growth Factor for the Treatment of Lower Extremity Ulcers.  Plastic and Reconstructive Surgery. 2006;  117 (7S) 143-149 71–81
    Google Scholar
  • 37 Steed DL, Donohoe D, Webster MW and the Diabetic Ulcer Study Group et al. Effect of extensive Debridement and Treatment on the Healing of Diabetic Foot Ulcers.  J Am Coll Surg. 1996;  183 61-64
    Google Scholar
  • 38 Hinchliffe RJ, Valk GD, Apelqvist J. et al . A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes.  Diabetes Metab Res Rev. 2008;  24 (S 01) S119-S144
    Google Scholar
  • 39 Higgins J, Altmann DG. Assessing risk of bias in included studies. In: Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 5.0.0. Oxford, UK: The Cochrane Collaboration; 2008
    Google Scholar

Correspondence

Dr. B. Buchberger

University of Duisburg-Essen

Schuetzenbahn 70

45127 Essen

Germany

Phone: + 49/(201) 1834075

Fax: + 49/(201) 1834073

Email: barbara.buchberger@medman.uni-due.de

      >